WEEKLY TRELAGLIPTIN IMPROVES QUALITY OF LIFE IN TYPE 2 DIABETIC PATIENTS OF HYDERABAD, SINDH, PAKISTAN
Main Article Content
Keywords
Trelagliptin, weekly, Hyderabad, Diabetes
Abstract
Introduction
Type 2 diabetes is alarmingly increasing all over the globe. The oral anti diabetics are facing compliance problems, cost and limited improvement in quality of life. The DPP4 inhibitors increase incretin levels and have no chances of hypoglycemia thus improve overall quality of life.
Objective
To assess improvement in quality of life in type 2 diabetes mellitus, pre and post use of weekly trelagliptin attended OPD of Liaquat University Hospital Hyderabad / Jamshoro Sindh Pakistan
Study Design& duration. Quasi-experimental.
Study Setting; OPDs of Liaquat University Hospital Hyderabad / Jamshoro and
Duration of Study; July 2023 to October 2023
Methodology: 340 patients with type 2 diabetes for at least 2 years duration, already on metformin with or without glimepiride, age limit from 25-60 years of either gender were selected by nonprobability consecutive method. All patients had under gone for estimation of BMI, HbA1c and inquired for health related quality of life by LUMHS designed questionnaire. That questionnaire was designed after searching data base. 5 items calibrated from good to poor life quality such as finance, diet, sexual active, energy level and memory. Pre and post trelagliptin weekly given for 3 months and mean of pre and post response was assessed. The change of mean > 1.3 or Rubric > 10 score signified better health related life. Reduction in HbA1c of at least ≥0.5% from the baseline and at 3 months was considered as secondary outcome achieved by weekly trelagliptin.
Results; 340 patients were selected, the mean age was 47 ±4.89 years. There were 220 males (65%) and 120 (35%) males. There is a significant proportion of males aged 47-60 years (61%) compared to females (37.5%). A higher percentage of females are married (79%). Females have a slightly higher mean BMI (25 ± 1.4) compared to males (24 ± 1.2). The values indicate that males have a higher average HbA1c level 0.5 compared to females 0.3. The pre and post Trelagliptin showed the variables Finance, Diet, Energy Level, and Sexual Activity showed statistically significant differences between males and females, with P-values less than 0.05. Memory, however, does not show a significant difference.
Conclusion: Weekly trelagliptin improved quality of life as well as HbA1c and it also better tolerated.
References
2 Pladevall M, Williams LK, Potts LA, et al Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004; 27: 2800–2805
3 Gribble FM. Targeting GLP-1 release as a potential strategy for therapy of Type 2 diabetes RD Lawrence Lecture 2008. Diabetic Medicine. 2008;25:889–894.
4 Drucker DJ. Dipeptidyl Peptidase 4 inhibition and the treatment ofType 2 diabetes. Diabetes Care. 2007;30:1335– 1343.
5 Inagaki N, Onouchi H, Sano H, et al SYR‐472, a novel once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol 2014; 2: 125–132
6 Mannucci E, Bardini G, Ricca V et al. Predictors of diabetes-related quality of life. Diabetologia. 1997;40:A640.
7 Quah JH, Luo N, Ng WY et al. Health-related quality of life is associated with diabetic complications, but not with short-term diabetic control in primary care. Ann Acad Med Singapore. 2011;40:276–86.
8 Arokiasamy, P., Salvi, S. & Selvamani, Y. Global burden of diabetes mellitus: Prevalence, pattern, and trends. in Handbook of Global Health, 495–538 (2021).
9 Ur Rahman J, et al. Assessment of prescribing patterns and medication errors related to prescriptions in hospitalized diabetes mellitus type-2 patients in Khyber Pakhtunkhwa, Pakistan. J. Pharm. Health Services Res. 2023;14:49–54
10 Japan Diabetes Society. Treatment guide for Diabetes 2016–2017. 2016.
11 Inagaki N, Onouchi H, Maezawa H et al. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol. 2015;3:191–197
12 Inagaki N, Sano H, Seki Y et al. Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study. J Diabetes Investig. 2018;9:354–359
13 Ishii H, Suzaki Y, Miyata Y, Matsui S. Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor. Diabetes Ther. 2019 Aug;10(4):1369-1380.\
14 Inagaki N, Onouchi H, Maezawa H, et al Once‐weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double‐blind, phase 3, non‐inferiority study. Lancet Diabetes Endocrinol 2015; 3: 191–197.
15 Ishii, H., Suzaki, Y., Miyata, Y. et al. Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor. Diabetes Ther 10, 1369–1380 (2019)
16 Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. S Med J. 2002;95:68–71
17 Inagaki N, Sano H, Seki Y et al. Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study. J Diabetes Investig. 2018;9:354–359.
18 Ishii H, Suzaki Y, Miyata Y. Effect of Trelagliptin on Quality of Life in Patients with Type 2 Diabetes Mellitus: Study Protocol. Diabetes Ther. 2017 Dec;8(6):1415-1425
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Imran Ali Shaikh
FCPS, FACP, FRCP, FPSIM, Professor of Medicine, Liaquat University of Medical and Health Sciences Jamshoro Sindh, Pakistan
Dr. Kanwal Abbas Bhatti
FCPS (Med), FCPS (Endo), Associate Professor of Medicine, Liaquat University of medical and health sciences Jamshoro Sindh, Pakistan
Dr. Tarique Zaffar Shaikh
MBBS, MD, Assistant Professor of Medicine, Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro Sindh, Pakistan
Dr. Naila Masood
MD, FACP, FRCP, FPSIM, Professor of Medicine, Liaquat University of Medical and Health Sciences Jamshoro, Sindh, Pakistan
Dr. Abdul Ghaffar Daras
MBBS, FCPS, Assistant Professor of Medicine LUMHS, Liaquat University of Medical and Health Sciences Jamshoro Sindh, Pakistan
Dr. Yasra Memon
MBBS, MD, Women Medical Officer/ Consultant. Medical Unit 1, Liaquat University Hospital, Hyderabad, Pakistan